Clario specializes in generating clinical evidence for medical research by combining scientific expertise with a wide range of endpoint technology. Their products support various types of clinical trials, including decentralized, hybrid, and site-based trials, allowing for flexibility in how studies are conducted. Clario stands out from competitors due to its extensive experience, having participated in nearly 19,000 clinical trials and achieved 870 regulatory approvals, which provides a high level of reliability in the data they produce. The company's goal is to empower partners in the healthcare industry to improve patient outcomes by providing comprehensive and trustworthy clinical evidence.

Biotechnology

Healthcare

Clairo

PHILADELPHIA - October 10, 2024 - Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency.

Clario and PathAI Collaborate to Deliver Integrated Solution for GI Clinical Trials

Title: "Clario, Drug Trial Software Maker, Files Confidential IPO Dossier"

Content:
Clario, a software maker for drug trials, has filed a confidential dossier for an IPO, aiming for a valuation of over $10 billion, according to Bloomberg News.

Clario Files for $10B IPO

Clario, a provider of software to help drugmakers advance treatments through clinical trials, has filed confidentially for an initial public offering and is targeting a valuation of more than $10 billion, people familiar with the matter said.

Drug-Trial Software Maker Clario Files Confidentially for IPO

With the FDA 510(k) clearance of the COR-12 wireless ECG device now integrated with the SpiroSphere®, sponsors can conduct comprehensive respiratory trials with cardiac safety ECG collection on one device.Clario's SpiroSphere® integration with the wireless COR-12 is now FDA 510(k) cleared, allowing for consecutive collection of spirometry and ECG data during a single site visit.The flexibility of the wireless COR-12 ECG enables integrated respiratory and cardiac safety trials for on-site, hybrid or remote trial design considerations.The wireless feature of the SpiroSphere® ECG improves patient experience by removing the need for lead wires while maintaining high-quality data collection and accelerating trial timelines.PHILADELPHIA, June 13, 2024 /PRNewswire/ -- Clario, a leading provider of technologies and endpoint data solutions for clinical trials, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for its SpiroSphere® with the wireless COR-12 Electrocardiogram (ECG) device. This technological advancement allows for the consecutive collection of spirometry and ECG data during a single site visit through Clario's SpiroSphere® platform, consolidating all data into a single, unified database. This streamlines the clinical trial process and eliminates the need for separate ECG devices or multiple databases for a study.Originally launched in 2018, the SpiroSphere®, a smart and lightweight pulmonary function testing (PFT) device, initially did not include ECG functionality. Now, the introduction of the SpiroSphere® ECG features the wireless COR-12 ECG device. This advancement enables customers to run integrated respiratory and cardiac safety trials on a single device and single database, simplifying the clinical trial process."The launch of our FDA-cleared SpiroSphere® wireless ECG device represents a significant step in improving clinical trial technology," said Tom Stuckey, Senior Vice President, Respiratory & Precision Motion at Clario

Fda Clears Clario'S Spirosphere® With Wireless Ecg, Streamlining Data Collection In Clinical Trials

Clario partners with Emsere to extend ophthalmic medical imaging capabilities for clinical trials.

Clario partners with Emsere to extend ophthalmic medical imaging capabilities for clinical trials

Image Credit: Women’s health, legislation, and financial collage/ Nicole Bean for BiospaceThe focus on prioritizing women’s health has slowly been increasing throughout the life sciences and healthcare industries in recent years. Still, women’s health is underfunded, with only 2% of the $41.2 billion funding granted by venture capitalists in 2023, according to a Deloitte analysis of PitchBook data.Last month, President Biden signed an Executive Order on Advancing Women’s Health Research and Innovation. This is a huge step forward to jumpstart funding and incentivizing women’s health research, not only in the United States, but on a global scale. This monumental step highlights the significant opportunities and challenges presented in women’s health.Federal FundingThrough the White House Initiative on Women’s Research, launched in 2023, the Biden Administration has already committed over $300 million funding—$100 million through the  Advanced Research Projects Agency for Health’s Sprint for Women’s Health initiative plus the National Institutes of Health’s pledge of $200 million dedicated to close gaps in women’s health research starting in FY2025. The new executive order expands the commitment and spotlight on women’s health by calling on Congress to commit $12 billion to the funding of new women’s health research across the federal agencies over a period of years, which remains unspecified at the time of this article’s publication.Kathyrn G. Schubert, president and CEO of the Society for Women’s Health Research, a non-profit organization focused on increasing women’s health funding, spoke with BioSpace after attending the executive order’s signing

Can $12 Billion Jumpstart Women’S Health?

Legal and compliance expert Julia James, previously with Thermo Fisher Scientific, joins Clario to drive legal and compliance strategy PHILADELPHIA, April 8, 2024 /PRNewswire/ -- Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the appointment of Julia James as the company's Chief Legal and Administrative Officer. This appointment bolsters Clario's strategic focus on improving the customer experience and differentiating its offerings. Julia James, Chief Legal and Administrative Officer, Clario. "We are excited to welcome Julia James to Clario," said Chris Fikry, M.D., Chief Executive Officer at Clario. "Her extensive legal and compliance expertise will help us continue to advance Clario's impact in clinical trials, further enhancing our efforts on quality and speed to empower our partners to transform lives." Julia served as Executive Vice President and General Counsel of PPD, the leading contract research organization, until its acquisition by Thermo Fisher Scientific in 2021. She then continued as General Counsel, Clinical Research, following the transaction

Clario Appoints Julia James As Chief Legal And Administrative Officer

Acquisition advances Clario's Respiratory Solutions portfolio, combining Clario's deep scientific expertise with ArtiQ's innovative artificial intelligence capabilitiesClario's respiratory devices will integrate seamlessly with ArtiQ's AI models to provide instant feedback on test quality, delivering faster, more reliable data for sponsors and yielding a better patient experience.The addition of ArtiQ, coupled with Clario's recent acquisition of Inofab Health, expands Clario's leadership position in supporting respiratory clinical trials and broadens the existing AI capability which encompasses over 50 proprietary AI/ML algorithms.ArtiQ CEO Marko Topalovic will join Clario and continue to lead ArtiQ while simultaneously leading AI at the company.PHILADELPHIA, April 2, 2024 /PRNewswire/ -- Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the acquisition of the technology company ArtiQ. This acquisition expands the power of artificial intelligence (AI) in Clario's Respiratory Solutions portfolio and enhances the company's ability to further leverage and develop innovative uses of AI across its service lines."We're thrilled to welcome ArtiQ into our organization," said Chris Fikry, Chief Executive Officer at Clario. "Since 2018, Clario has been a pioneer in applying artificial intelligence to improve the quality and efficiency of clinical trial execution. This move significantly advances AI within our respiratory portfolio. With ArtiQ's technology, we are expanding our ability to rapidly scale AI for overreading while ensuring data quality and streamlining the clinical trial process for patients worldwide."In addition to continuing to lead ArtiQ, Marko Topalovic will step in to lead Clario's overall AI strategy across the organization. Of the acquisition, he said: "Joining forces with Clario is a pivotal moment for ArtiQ

Clario Announces Acquisition Of Ai-Powered Software Company Artiq

The ISO 27001 certification validates Clario's systematic and comprehensive approach to information security management practices and recognizes the Company's strong commitment to protecting sensitive information.PHILADELPHIA, Feb. 21, 2024 /PRNewswire/ -- Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the achievement of ISO 27001:2022 [ISO/IEC 27001] certification, a globally recognized standard for information security management systems (ISMS). This certification validates Clario's systematic and comprehensive approach to safeguarding sensitive information.The ISO 27001 certification is awarded to organizations that meet stringent criteria for establishing, implementing, maintaining, and continually improving information security management practices. The certification is a testament to Clario's unwavering commitment to maintaining the highest standards of information security for its customers and stakeholders."In the rapidly evolving digital landscape, information security is critical for our customers and our organization," said Jay Ferro, EVP, Chief Information, Technology & Product Officer at Clario. "This milestone highlights Clario's commitment to upholding the confidentiality, integrity, and availability of information assets, as well as the continuous enhancement of our information security processes.""Trust is paramount in today's digital age," said Murtaza Nisar, VP, Chief Information Security Officer at Clario. "Clario is committed to building better trust with our customers through third-party security assurances

Clario Achieves Iso 27001 Certification, Demonstrating Commitment To Information Security

PHILADELPHIA, PA - December 11, 2023 - Clario, a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, today released its second annual Environmental, Social, and Governance (ESG) report.

Clairo

Generates clinical evidence for trials

Clairo

Generates clinical evidence for trials

About

Simplify's Take

What believers are saying

What critics are saying

What makes Clairo unique

Benefits

Recently Posted Jobs

Clairo is Hiring for 0 Jobs on Simplify!